Eli Lilly and Company (India) has launched Mounjaro (tirzepatide), a once-a-week injectable prescription medication, ...

Metabolex has entered into an agreement with Sanofi ... Diabetes Centre at the University of Toronto, Canada. This promise has already been supported through the development of T2D drugs that ...

Sanofi’s strategy of betting on new drugs ... a 3-5% increase in earnings per share for 2019. Patent expiries in diabetes drugs like Lantus have taken their toll on previous earnings, and ...

Sanofi has agreed a deal to buy US biopharma company Provention Bio for $2.9 billion, taking control of a recently-approved type 1 diabetes (T1D) prevention therapy Tzield that has been tipped as ...

Sanofi–Aventis has signed an agreement with ... pancreatic islet neogenesis — for the treatment of type 1 and type 2 diabetes. The agreement for this preclinical-stage agent involves an ...

Pharma group Hikma looks to take advantage as Novo Nordisk’s Wegovy and Ozempic start to go off patent next year ...

1 "The FDA has now approved three biosimilar insulin products to treat diabetes," said Peter Stein, MD, director, office of new drugs, FDA's Center for Drug Evaluation and Research, in a press release ...

Biosimilars are near-identical versions of FDA-approved biologic drugs, offering the same safety and effectiveness. Diabetes is a condition ... Merilog, made by Sanofi-Aventis, is a rapid-acting ...

NEW YORK, March 5, 2025 /PRNewswire/ -- Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less ... Health Education, Sanofi, Thermo-Fisher ...

The agency has given a thumbs up to Sanofi’s Merilog (insulin-aspart-szjj) as the first biosimilar to Novo Nordisk’s NovoLog for patients with diabetes ... are among the drugs subject to ...